Head-To-Head Survey: Cooper Companies (COO) & TearLab (TEAR)

Cooper Companies (NYSE: COO) and TearLab (OTCMKTS:TEAR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Dividends

Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. TearLab does not pay a dividend. Cooper Companies pays out 0.9% of its earnings in the form of a dividend.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Cooper Companies and TearLab, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cooper Companies 0 5 8 0 2.62
TearLab 0 0 4 0 3.00

Cooper Companies presently has a consensus price target of $261.11, suggesting a potential upside of 9.34%. TearLab has a consensus price target of $5.75, suggesting a potential upside of 1,150.00%. Given TearLab’s stronger consensus rating and higher possible upside, analysts plainly believe TearLab is more favorable than Cooper Companies.

Profitability

This table compares Cooper Companies and TearLab’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cooper Companies 16.45% 16.00% 9.90%
TearLab -60.22% N/A -75.54%

Earnings and Valuation

This table compares Cooper Companies and TearLab’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cooper Companies $1.97 billion 5.94 $273.91 million $6.97 34.26
TearLab $28.01 million 0.09 -$19.92 million ($3.10) -0.15

Cooper Companies has higher revenue and earnings than TearLab. TearLab is trading at a lower price-to-earnings ratio than Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

96.8% of Cooper Companies shares are held by institutional investors. Comparatively, 12.2% of TearLab shares are held by institutional investors. 1.6% of Cooper Companies shares are held by company insiders. Comparatively, 12.0% of TearLab shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Cooper Companies has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, TearLab has a beta of 2.7, meaning that its share price is 170% more volatile than the S&P 500.

Summary

Cooper Companies beats TearLab on 10 of the 15 factors compared between the two stocks.

About Cooper Companies

The Cooper Companies, Inc. is a global medical device company. The Company operates through two business units: CooperVision, Inc. and CooperSurgical, Inc. CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses. CooperVision services three primary regions: the Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific. CooperVision offers spherical, aspherical, toric, multifocal and toric multifocal lens products in various modalities. CooperVision’s products are primarily manufactured at its facilities located in the United Kingdom, Puerto Rico, Hungary, Costa Rica and New York. CooperSurgical offers an array of products and services focused on advancing the health of families through a portfolio of products and services focusing on women’s health, fertility and diagnostics.

About TearLab

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor’s office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Receive News & Ratings for Cooper Companies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply